Astrazeneca (AZN) Free Cash Flow (2009 - 2026)

Astrazeneca has reported Free Cash Flow for 18 years, with the latest figure at $3.6 billion in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 10.31% year-over-year to $3.6 billion in Q2 2026; TTM through Jun 2026 was $16.7 billion, a 7.24% increase from a year earlier, with the FY2025 full-year figure at $17.4 billion, up 26.12% from the prior year.
• Free Cash Flow was $3.6 billion for Q2 2026 at Astrazeneca, down from $3.9 billion in the prior quarter.
• The five-year high for Free Cash Flow was $8.0 billion in Q4 2023, with the low at $1.5 billion in Q2 2022.
• Average Free Cash Flow over 5 years is $4.0 billion, with a median of $3.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 325.62% in 2022, then sank 54.61% in 2024.
• Over 5 years, Free Cash Flow stood at $7.4 billion in 2022, then grew by 7.49% to $8.0 billion in 2023, then sank by 54.61% to $3.6 billion in 2024, then fell by 6.56% to $3.4 billion in 2025, then increased by 7.4% to $3.6 billion in 2026.
• The last three Free Cash Flow figures came in at $3.6 billion (Q2 2026), $3.9 billion (Q1 2026), and $3.4 billion (Q4 2025), per Business Quant data.